Stevens Institute of Technology (Stevens), Hoboken, NJ, has signed an exclusive licensing agreement with health and technology company Bonbouton, New York, giving Bonbouton the right to use and further develop a graphene sensing system that detects early signs of diabetic foot ulcers (DFUs) before they form. Left untreated, DFUs can cause severe tissue and bone damage and may ultimately lead to amputation.
Bonbouton founder and CEO Linh Le, PhD, developed and patented the core graphene technology while pursuing a doctorate in chemical engineering at Stevens. The smart insole, powered by non-rechargeable batteries, comprises a top fabric layer, a flexboard sensor layer, and cushioned bottom layer. They can be inserted into a sneaker or dress shoe to passively monitor the patient’s foot health. The insoles sense the skin’s temperature (changes as small as 0.1 degree Celsius can be detected), pressure, and other foot health–related data. The data is then sent via Bluetooth to a companion app that can be accessed by the patient and shared with their healthcare provider, who can determine if intervention or treatment is needed.